Expansion of Indications to Degenerative Spinal Disease
Patents Acquired in the United States and Australia

Kolon TissueGene announced on May 26 that it has obtained patents in the United States and Australia for expanding the application of its cell and gene therapy for osteoarthritis, TG-C, to degenerative spinal (disc) disease, in addition to its current indications under development.


With these newly acquired patents, following the European patent obtained in July last year, Kolon TissueGene has further solidified the exclusive global rights to TG-C. Building on this momentum, the company will now embark on global clinical development for the disc (spinal) indication. The process will begin with the selection of a contract research organization (CRO) for the spinal indication clinical trial, and in the second half of the year, Kolon TissueGene plans to obtain approvals from the Institutional Review Board (IRB) and Institutional Biosafety Committee (IBC) in the United States to ensure the smooth progress of clinical procedures.

Kolon TissueGene TG-C to Begin Full-Scale Clinical Trials for Spine Following Knee Indication View original image

The TG-C samples to be used in the spinal clinical trial are scheduled to be supplied by Lonza, which also produced clinical trial samples for the knee indication. Once the samples are provided, the company will designate clinical trial hospitals in the United States and initiate dosing procedures for patients with degenerative spinal disease starting in December this year. The trial will enroll a total of 24 participants, who will be evaluated approximately 12 times over a 24-month period following administration.


Seung Ho Jeon, CEO of Kolon TissueGene, stated, "For the spinal indication, initial clinical results may create strategic opportunities such as out-licensing, thus diversifying our commercialization strategy. Beginning with the top-line results announcement for TG-C’s phase 3 clinical trial for the knee indication scheduled for July, we plan to expand indications to the hip and spine to maximize the market value of TG-C."


Previously, in December 2023, Kolon TissueGene received FDA approval for a phase 1 clinical trial of TG-C for the spinal indication. According to Bruder Consulting, a U.S.-based consulting firm, the potential annual market size in the United States for TG-C’s spinal indication is estimated to reach between 1 billion and 3 billion dollars (approximately 1.3 trillion to 4 trillion won).



Meanwhile, Kolon TissueGene is increasing its market value by expanding indications beyond the knee to the hip and spine. In particular, for the hip indication, since the pathological features of the disease are similar to the knee, the company was able to skip preclinical and phase 1 clinical trials and obtain FDA approval for a phase 2 clinical trial in December 2021. If the ongoing phase 3 knee trial is successfully completed, Kolon TissueGene plans to establish a detailed clinical implementation plan for the hip indication.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing